Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolarity II Depression and Suicide prevention
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Understand this study
Who could participate?
This study is for people with type II bipolarity. Listed age limits: 25 years to 70 years. Other eligibility criteria apply.
- Listed locations
- Houston, United StatesSee all locations and recruitment
- Activities
- Medication described in the protocol · Behavioural activities described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 10
- Sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 25 Years to 70 Years
- Official registry ID
- NCT06706232
Recruitment & locations
RecruitingHouston
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is The University of Texas Health Science Center, Houston, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
This study is for people with type II bipolarity. Listed age limits: 25 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me